ArQule’s Portfolio

Lead

Optimization

GLP

Tox

IND

Filed

Phase

I II II

Program

Mkt

NDA

Filed

ArQ 501

E2F

#2

ArQ 101

Wyeth

Solvay

Novartis

ACT

Biology

Pfizer

CSPs

PUMA

p53

Target ID

Validation

Lead

Generation

Previous slide

Next slide

Back to first slide

View graphic version